Sentinel node biopsy in breast cancer patients after receiving chemotherapy prior to surgery.

Comparative study of targeted sentinel node biopsy versus axillary sampling in clinically node negative breast cancer after neo-adjuvant chemotherapy

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

CTRI

Registry ID

CTRI/2015/11/006382

Enrollment

750

Registered

2015-11-26

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Locally advanced or large operable breast cancer

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Confirmed locally advanced or large operable breast cancer 2. No prior excision biopsy 3. Clinically node negative breast cancer after neo-adjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Clinically node positive breast cancer after neo-adjuvant chemotherapy

Design outcomes

Secondary

Measure	Time frame
1. Number of times the sentinel node is found within the sampled nodes 2. Sensitivity in predicting status of rest of axillary nodes 3. False negative rate by both methods. 4. Negative predictive value for both methods. Timepoint: From the day of surgery to post operative Day 15	—

Primary

Measure	Time frame
1. Number of nodes identified by sentinel node biopsy and axillary sampling 2. Number of times the sentinel node is found within the sampled nodes 3. Sensitivity in predicting status of rest of axillary nodes 4. False negative rate by both methods. 5. Negative predictive value for both methods. Timepoint: frm the day of surgery to post op Day 15	—

Countries

India

Contacts

Public ContactDr Vani Parmar

Tata Memorial Hospital, Mumbai, India

vaniparmar@gmail.com912224177194

Outcome results